Last Updated : May 14, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Twynsta | Telmisartan/ Amlodipine | Hypertension | List | Complete | ||
Twynsta | Telmisartan / Amlodipine | Hypertension | Cancelled | |||
Tykerb (in combination with Letrozole) | Lapatinib | Metastatic Breast Cancer | Do not reimburse | Complete | ||
Tysabri | natalizumab | Multiple Sclerosis, relapsing-remitting | Withdrawn | |||
Tysabri | Natalizumab | Multiple Sclerosis, relapsing-remitting | List with clinical criteria and/or conditions | Complete | ||
Tysabri | Natalizumab | Multiple Sclerosis, relapsing-remitting | Do not list | Complete | ||
Uloric | Febuxostat | Gout | List with clinical criteria and/or conditions | Complete | ||
Ultibro Breezhaler | Indacaterol/glycopyrronium | Chronic obstructive pulmonary disease | List with criteria/condition | Complete | ||
Ultomiris | ravulizumab | Neuromyelitis optica spectrum disorder (NMOSD) | Reimburse with clinical criteria and/or conditions | Active | ||
Ultomiris | ravulizumab | AChR antibody-positive generalized Myasthenia Gravis | Do not reimburse | Complete |